Resonance Health Temettü

Temettü kriter kontrolleri 0/6

Resonance Health şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Geri Alım Getirisi

Toplam Hissedar Getirisi	n/a
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Mar 01

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Jan 15

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Nov 22

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RHT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RHT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Resonance Health Piyasaya Karşı Temettü Getirisi

RHT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RHT)	n/a
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (RHT) (3 yıla kadar)	n/a

Önemli Temettü: RHT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RHT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RHT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RHT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Resonance Health Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Resonance Health Limited, Annual General Meeting, Nov 28, 2024

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.002 loss in FY 2023)

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

New minor risk - Share price stability

New minor risk - Share price stability

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in FY 2022)

New minor risk - Financial data availability

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)

Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

FerriScan Now Available on 3 Tesla (3T) MRI Machines

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited Receives United States CPT Code Confirmation for Liversmart

Resonance Health Limited Announces US FDA Clearance for LiverSmart

Resonance Health Ltd Provides Update on its Antisense Oligonucleotide Project for Treating Viral Hepatitis

Resonance Health Limited Announces Filing of Two Patent Applications

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Resonance Health Ltd announces R&D Molecular Medicine ASON Project Results of Dosing Study

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Chief Executive Officer Alison Laws has left the company

Resonance Health Limited Announces Filing of Patent Application

Resonance Health Limited Provides Update on Its Antisense Oligonucleotide R&D Project for Treating Liver Related Diseases

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Resonance Health Ltd HepaFat-AI Receives CE Marking

Resonance Health Ltd Receives Australian Therapeutic Goods Administration Approval for HepaFat-AI

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Resonance's HepaFat-AI Incorporated into Blackford Analysis

New 90-day high: AU$0.28

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Resonance Health Ltd Develops New Artificial Intelligence Tool for the Automated Review of Chest Computed Tomography Scans of Patients with Suspected Pulmonary Embolism

Full year earnings released - AU$0.0017 loss per share

Full year earnings released - AU$0.0017 loss per share

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin